Boehringer Ingelheim Spiolto Respimat (tiotropium / olodaterol) once-daily maintenance treatment has received regulatory authority approvals in first European countries, to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Spiolto Respimat has been developed on tiotropium, which is the active ingredient in Spiriva and enhanced by olodaterol, is a long-acting beta2-agonist with fast onset action. Spiolto is delivered by Respimat inhaler.
Spiriva is said to be the world’s most prescribed COPD maintenance treatment with more than 40 million patient years of real-life experience across all COPD severities.
Boehringer Ingelheim chief medical officer Klaus Dugi said: "Since its first launch in 2002, Spiriva has brought medical benefits that have made a real difference to the lives of millions of patients with COPD around the world.
"Spiolto Respimat is our newest advance in COPD treatment. Its recent approval in the US, Canada and Australia, alongside the approval in countries across Europe, is an important step forward in our ongoing commitment to provide effective solutions for patients with COPD.
"We anticipate further approvals of Spiolto Respimat in other European countries over the coming months."
Regulatory approvals are based on data from the Tonado 1 and 2 clinical trials, which involved more than 5,000 patients.
The Tonado trials are part of the TOviTO clinical programme, involving more than 15,000 patients, which showed Spiolto Respimat provides clinically relevant improvements over Spiriva.
COPD, which is predicted to become the third leading cause of death by 2030, is a chronic, progressive, treatable but incurable lung disease that affects 210 million people worldwide.
Image: A chest X-ray showing severe COPD. Photo: courtesy of James Heilman, MD.